The cancer-associated "R462Q" mutation results in a glutamine instead of an arginine at position 462 of the RNase L enzyme, reducing its catalytic activity.
At position 462 of the RNase L enzyme, the "R462Q" mutation results in a glutamine rather than an arginine, thereby diminishing its catalytic efficiency.